https://scholars.lib.ntu.edu.tw/handle/123456789/537526
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | Wang J.-D. | en_US |
dc.contributor.author | Hwang J.-S. | en_US |
dc.contributor.author | HWEI-FANG TIEN | en_US |
dc.contributor.author | Chang S.-M. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | YAO-CHANG CHEN | en_US |
dc.contributor.author | JIH-LUH TANG | en_US |
dc.date.accessioned | 2021-01-04T12:13:01Z | - |
dc.date.available | 2021-01-04T12:13:01Z | - |
dc.date.issued | 2003 | - |
dc.identifier.issn | 0962-9343 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042856382&doi=10.1023%2fA%3a1025043113819&partnerID=40&md5=04be144844ebccc8cf37639619d523c7 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/537526 | - |
dc.description.abstract | The objective of this study was to use survival-weighted psychometric scores (SWPS) to construct a 'health profile' for long-term survivors of acute myelogenous leukemia (AML). The study cohort included all patients who had been diagnosed and treated in our institution from 1985 to 1999 and achieved complete remission after standard chemotherapy (n = 259). One hundred and four patients were interviewed by the European Organization for the Research and Treatment of Cancer (EORTC)-QLQ-C30 questionnaire and the brief form of World Health Organization quality of life questionnaire (WHOQOL-BREF) to estimate the quality of life (QOL) function of the cohort. Forty-one patients underwent bone marrow transplantation (BMT) as consolidation or salvage therapy; 63 received chemotherapy alone. SWPS for every functioning domain and symptom item was obtained by direct integration of the mean QOL function with the survival function of the cohort. A Monte Carlo method was used to extrapolate the life-long SWPS beyond the follow-up limit. The mean scores of EORTC-QLQ-C30 and WHOQOL-BREF did not differ significantly between patients who received BMT or those who received chemotherapy only (p > 0.01). In mean SWPS, patients who received BMT had significantly (p < 0.01) better SWPS in all of the functioning domains and symptom items of EORTC-QLQ-C30 and all four domains of WHOQOL-BREF. However, when the life-long extrapolation of SWPS was made, these differences diminished in global health and several symptom items of EORTC-QLQ-C30 as well as in the social and environmental domains of WHOQOL-BREF. Patients' perspective on QOL may be domain-specific and may evolve over time. SWPS may be useful to evaluate the efficacy of different treatment strategies for AML. Confirmation of the relative merit of BMT vs. chemotherapy alone from prospective studies is needed. | - |
dc.relation.ispartof | Quality of Life Research | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antineoplastic agent; acute granulocytic leukemia; adolescent; adult; aged; article; bone marrow transplantation; cancer chemotherapy; cancer survival; comparative study; drug induced disease; environmental factor; female; health status; human; major clinical study; male; Monte Carlo method; priority journal; psychometry; quality of life; questionnaire; social aspect; symptomatology; Adolescent; Adult; Bone Marrow Transplantation; Female; Health Status Indicators; Humans; Leukemia, Myelocytic, Acute; Male; Psychometrics; Quality of Life; Survivors | - |
dc.title | Survival-weighted health profile for long-term survivors of acute myelogenous leukemia | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1023/A:1025043113819 | - |
dc.identifier.pmid | 13677495 | - |
dc.identifier.scopus | 2-s2.0-0042856382 | - |
dc.relation.pages | 503-517 | - |
dc.relation.journalvolume | 12 | - |
dc.relation.journalissue | 5 | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-1384-5593 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0003-4021-3281 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。